GLP-1 Drug Costs Could Drop from $400 to $15 Monthly in Canada
Monthly costs for GLP-1 medications in Canada could drop from up to $400 to as low as $15 once generic competition enters the market, according to industry analysts tracking the pharmaceutical transition.
Current Canadian Pricing Landscape
According to recent market data, Canadians currently pay between $300 and $400 monthly for brand-name GLP-1 medications like Ozempic and Wegovy, with costs varying by dose and pharmacy. The Globe and Mail reports that Ozempic's list price in Canada stands at $223 for a four-week supply, though patients often pay higher amounts depending on their specific dosage requirements.
At Shoppers Drug Mart, Costco, Walmart, and Rexall locations across provinces including Ontario, British Columbia, Alberta, and Quebec, these medications represent one of the highest monthly prescription costs for patients without comprehensive coverage.
Projected Generic Pricing Impact
Market analysts predict dramatic price reductions once generic manufacturers enter the Canadian market. The New York Times analysis suggests that increased competition could drive generic prices down to approximately $15 monthly, representing a 96% reduction from current brand-name costs.
This projection aligns with Canadian generic pricing models, where generic semaglutide tracker data indicates patients can expect generics priced at roughly 35% of brand-name costs initially, with further reductions as more competitors enter the market.
Manufacturing Cost Analysis
Research published in Canadian Affairs News estimates that producing a month's supply of semaglutide could cost as little as $3, highlighting the significant markup potential in current pricing. This manufacturing cost analysis suggests substantial room for price competition once Health Canada approves pending generic applications.
The production cost data comes as nine generic manufacturers have active applications with Health Canada for semaglutide products, potentially creating a competitive marketplace that could drive prices toward manufacturing costs plus reasonable margins.
Patient Access Implications
The price differential between current and projected costs could significantly impact patient access across Canada. With Mounjaro and other GLP-1 medications also facing generic competition, the cost reduction could extend beyond semaglutide to the broader class of medications.
Provincial drug plans and private insurers are monitoring these developments, as lower generic prices could expand coverage eligibility and reduce plan costs. Patients can track coverage updates through the insurance coverage checker as policies adapt to the changing pricing landscape.
Regulatory Timeline Context
Health Canada continues reviewing the nine pending generic applications following the January 4, 2026 patent expiration. The regulatory body maintains a 180-day standard review timeline for generic submissions, with potential approvals expected throughout 2026.
Generic manufacturers including Sandoz, Apotex, Teva, Taro, Aspen, and Vimy Pharma have indicated various launch timelines pending regulatory approval. Additional information about the approval process is available in the FAQ section.
Market Competition Dynamics
The projected $15 monthly cost represents the potential endpoint of robust generic competition rather than initial generic pricing. Early generic entrants may price products at higher margins initially, with costs declining as additional manufacturers receive Health Canada approval and enter the Canadian market.
International precedent from other patent expiration events suggests that meaningful price reductions typically occur within 12-18 months of the first generic approval, particularly when multiple manufacturers compete simultaneously.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
